Investors
Quarterly Reports
Q3 2019 Report
Tuesday, 19 NovemberArctic Securities, Haakon VIIs gate 5, OsloThe webcast will be streamed LIVE and the recording will be available after LIVE session is finished.
Link to live webcastScientific Presentations
ASH 2019, Sonja Loges et al
9 December 2019Orlando, USA
Durable responses observed in elderly AML patients ufit for intencive chemotherapy with First-in-Class selective AXL inhibitor bemcentinib (BGB324) in combination with LDAC: Phase II open-label study.
Read More
Annual Report 2018
BerGenBio (OSE:BGBIO) is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases, including immune evasive, drug resistant and metastatic cancers.
Our annual report
Jonas Lies vei 91, 5009 Bergen, Norway
+ 47 559 61 159